Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Urinary Bladder Neoplasms 3Carcinoma, Transitional Cell 3Neoplasms 2Head and Neck Neoplasms 2Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma of Lung 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 16Nivolumab 9atezolizumab 7Docetaxel 7Cyclophosphamide 5durvalumab 4Ipilimumab 4Gemcitabine 4avelumab 3Specimen Handling 3Radiotherapy 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Etoposide 3Carboplatin 3temsirolimus 2spartalizumab 2sargramostim 2fludarabine 2epacadostat 2enzalutamide 2cabozantinib 2aldesleukin 2abiraterone 2Therapeutics 2Standard of Care 2Radiosurgery 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Rogaratinib × Genitourinary × Clear all
NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Bayer

Phase 2 Completed
1 enrolled
BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡